CEO/Founder
Biograil
Biograil is developing BIONDD®, a capsule-based platform that enables oral delivery of biologic drugs that currently require injection. The technology uses a spring-loaded device that attaches to the stomach wall to release medication for systemic distribution, with preclinical data showing bioavailability comparable to subcutaneous injections. The company is targeting pharmaceutical partners seeking to reformulate injectable biologics into oral dosage forms.
- Healthcare Technology
- Medical Devices
- Biotechnology
- Hardware
Updated 2 days ago
Funding
Raised to date
€34.7MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Est. $37.8Macross 4 rounds
AGEVHT+3€20M · Series B
Announced Nov 2026 · from article date
Disclosed cumulative: $37.8M
4/4
RoundDateAmountValuationInvestors
Founders
Product
Problem
Many biologic drugs require administration via injection, leading to patient discomfort, inconvenience, and potential compliance issues. This delivery method can also result in variable drug absorption and bioavailability, impacting therapeutic efficacy.
Solution
Biograil is developing BIONDD®, a capsule-based technology for the oral delivery of biologics. The capsule dissolves in the stomach and releases a device with a spring-loaded grabbing mechanism that safely attaches to the stomach wall, releasing medication into the tissue for systemic distribution. After drug delivery, the bio-compostable device passes safely through the GI tract. This approach aims to transform injectable pharmaceutical products into convenient oral capsules, eliminating the need for needles and improving patient adherence. Preclinical studies have demonstrated oral delivery of many injectable compounds with comparable bioavailability to subcutaneous injections.
Target Audience
Primary customers are pharmaceutical companies seeking to reformulate injectable biologics into oral dosage forms, as well as patients who require biologic therapies but prefer a non-invasive route of administration.
Features
- Standard size (double zero or single zero) capsule containing a device manufactured by injection molding
- Spring-loaded grabbing mechanism that attaches to the stomach wall for targeted drug delivery
- No mechanical moving components; relies on the body's own peristaltic forces for actuation
- Bio-compostable device that passes safely through the GI tract after drug delivery
- Applicable to currently marketed injectable pharmaceuticals and new chemical entities that cannot otherwise be delivered orally
- Preclinical data showing comparable bioavailability to subcutaneous injections for multiple compounds